meg tirrell with the latest. ty >> kelly, from today's hot stock to the year's hottest trade.hat would be energy the sector is higher today the only group to finish september in the green the surge in oil and natural gas prices supporting energy stocks, conventional energy stocks, i guess we should specify with oil near an three-year high opec considering boosting production when it meets on monday. there you see the charts damian corps vallen is head of energy research at goldman sachs. this week he raised his year-end price targets to $90 for brent and $87 for wti. damian, good to have you with us before we get to your price target and what you see ahead and whole question of distributed energy, i want to see whether i am understanding correctly what's going on in the marketplace. we've got supply problems in many, many, many parts of the global economy is supply fundamentally the reason -- lack of it, fundally the reason why energy price versus gone up as much as they have and why you see them continuing to be at this level are there supply constraints in the equation >> th

meg tirrell here with the details. g the first glimpse of highly anticipated results from a trial nih sponsored looking at what happens if you got a different brand of vaccine booster than you got for your primary series what this initial look which has been posted on a preprint server and not yet peer reviewed suggests if you got the j&j vaccine, you're served best by getting one of the boosters from the mrna vaccines. otherwise there was a slight showing that the moderna vaccine was the best booster if you got moderna first, you'd want that as a boost but it was hard to tell with moderna and pfizer both were close. a pretty close difference with j&j and getting the mrna vaccines this is so important for the commercial question for the companies because after this, they're competing commercely for who will be the booster of chose. moderna is up there because axios has reported this sand it's been up all day on this interestingly, you see companies like novavax which doesn't have that yet because it's matching up >> tha

administered roughly 133 doses for every 100 people poorer nations have administered just 4 doses meg tirrellers health and science for us meg, could we expect some catch-up or could the gap get wider? >> remember last year the world health organization and others created covax to ensure equitable distribution of vaccines but it's shown woefully short of its supply goals. the effort has raised more money than it set out to but hasn't been able to secure enough vaccine. as of last month it was 1.7 billion doses short of its goal of delivering 2 billion by the end of the year. as wealthy nations bought up supply, manufacturing setbacks reduced output some countries like india blocked exports among their own covid surges even as calls mounting for more delivery of doses themselves, there's been an increasing focus on the need to help administer them we spoke with the person who leads the covid response at usaid. >> in the next i would say three months or so, as vaccine volumes continue to grow and vaccine availability continues to improve, we'll see that become the limiting factor in more and mo

panel is meeting right now to discuss whether to recommend pfizer's vaccine for young children meg tirrell is here with the latest hi, meg. >> reporter: hey, kelley so the morning was spent by presentations from the cdc, the fda and from pfizer, all about the vaccine safety and efficacy in kids ages 5 to 11 remember, it is a third of the dose given to kids 12 and up and to adults. there was also a lot of discussion about the risk of covid itself to kids to try to help with that risk/benefit analysis the fda in its briefing documents saying about 22% of overall cases since the pandemic began have been in kids under 18, 8.7% in kids ages 5 to 11, the ages being discussed today more recently they say it is up to 39% deaths of kids under 18, 691 for the entire pandemic, 146 in this age group they're discussing today. so those numbers, while a lot lower than for adults obviously still tragic, and the reason a lot of folks say a vaccine is needed for kids. now, the main issue that they're talking about today is this risk of mayocarditis, the rare effec that can come with the vaccine the fda pres

. >> let's focus on the big stories of today mike santoli is tracking the action and meg tirrell watchinghe fda. mo broader markets? >> ugly on the index level if you count the overnight sessions it is jumpy within a range. a decent half percent selloff. fully recovered by the morning and 2% above last week's intraday low 4% below the highs there is this short term down trend with the rally fizzling out. that's something that has traders concerned and attempts at traction. that attempt at a low it is the style of a bottoming process that sometimes tacks effect. dialing back to last october it was a deeper pullback and did look like? if you look it is really the bigger stocks and that have been weighing on things the average stock in the market slightly outperforming the s&p 500. this is the yps. yet it spy backwards. s&p 500 stocks but weighted in reverse order so the smallest are weighted the largest the prices do reflect that upside down waiting and actually pretty good performance since the september 2 high in the s&p 500. outperformed the nasdaq 100. mega cap growth stocks with a big

cnbc's meg tirrell covers science and health for us and is on the top story tonight meg, break this meeting down if you could. did the panel have any real big concerns >> reporter: yeah, shep. the panel was a lot more divided on the recommendation than its vote would imply it came down to how these 18 medical experts viewed the benefit risk trade-off for the vaccine for kids in this age group. the benefits 91% efficacy in preventing cases of covid. potentially helping approach herd immunity and reducing transmission, and allowing kids to get back to school and life in a more normal way the risks, mainly mio car dieties, the heart inflammation that emerged as a rare side effect following the second doze of pfizer and moderna's vaccines, predominantly for young men. in younger kids the cases and side effects tended to be mild and resolved on their own, for one reason the dose is a third of what's given to adults and kids over 12, but the group grappled with those uncertainties. another point that came up is the number of kids who may have already had the virus and whether they need two shots

meg tirrell is looking at the vaccines just slipping a little be the in the last hour? >> certainly good to have three days straight in a row higher. we got relief but not really the rerisky move i do think maybe tomorrow's job number before the open might be a reason people wanted to flatten out when we did get to the highs. you have not quite taken care of that which is this developing down trend at the highs for the day the s&p 500 was very, very close to kind of closing up this big gap that was there from a week ago monday very close to going above the 50-day average missed those still up 3% from monday's lows why not bad for a few day's work responded to the conditions. all that stuff is positive but these things don't typically go in a straight line and explains maybe why we are fading slightly here today inclusive rally today. been saying since the highs in the market that the credit markets largely undisturbed. this isdating from right about when the s&p 500 made the peak in the very start of is ept. you have the riskiest corporate debt is joutperforming the saf

meg tirrell, it will be interesting.ession. if you check things out right now, helping them hire, we got united health, which feed on the top and bottom line for the third quarter. warm greens contributing to the dow's rise, those numbers were strong check these out, the dow is up 284. if you take a look at treasuries, we have been watching that closely. not as much movement there if you look at the yield, 30-year yield is sitting at 2.0343%. another check on the big banks, green arrows across the board, strong numbers this morning, too, bank of america is the biggest gainer it's up by 2.7%. wells fargo up 1.2%. >>> wells stanly and citigroup up by one and a third percent. >> coming up, want to visit europe united airline itself just came out with ambitious new plans to get you there. you will hear from a top airline executive when "squawk box" returns right after this in 2016, i was working at the amazon warehouse when my brother passed away. and a couple of years later, my mother passed away. after taking care of them,

cnbc's meg tirrell, easy for you to say, covers health and science for us brilliantly meg, what can youhis data? >> reporter: well, shep, this was the first u.s. results that we have seen mixing and matching a booster vaccine. they're from an nih trial of about 450 participants they looked at all different combinations of available vaccines, pfizer, moderna, johnson & johnson. what they found was a booster of any type will help but mixing types might increase antibody results even more. it was more pronounced for those who got j&j around the study notes every combination has a vaccine efficacy of 90% except a j&j boost to an original j&j shot. what's not clear is what the fda and cdc will do with this. they only looked at antibody responses. another arm of the immune system, t cells are important in its vaccine's protection in meetings this week the fda has only asked advisers whether to recommend boosters for moderna and j&j of the same vaccine type on friday afternoon they'll discuss the mix and match results. next week the cdc's advisers are meeting on boosters as well. it's possible

peter hotez on that and the pfizer covid vaccine for kids first, cnbc's meg tirrell on flu season meg? >> well, shep, it's october so that means pumpkins, costumes and flu vaccines that was the message from infectious disease doctors today who warned that it's typically after we all get together for thanksgiving that flu starts to take off so they say now is the time to get the flu shot to start building up protection of course flu was almost nonexistent last year, completely dwarfed by covid. as you can see from cdc data showing deaths caused by both diseases over the last few years. those little blue lines is blew, orange is covid. the distancing, masking and other measures we took because of the pandemic reduced the spread of flu, particularly closing schools. as those measures lift, we're likely to see that bug start to spread again cdc director dr. rochelle walensky also cautioning the return of other diseases like rsv could be a warning sign for what's to come this winter the agency says flu shot manufacturers are projected to ship a record number of doses to the u.s. this year,

spell a lot of hustling on this particular issue >> we appreciate you helping us out, meg that's meg tirrell with the vaccines on adolescents as first reported in "the wall street journal. forgive me, i wanted to get it from meg on this breaking story. today about atcore >> atcore has had a stellar performance. the stock got up to -- i may have sold it a point or two lower, but they're managing cost supply chain very well and it's a small company, and they're doing a great job, so it's a cheap stock at about 10, 11 times earnings and that's why i bought it. >> and jabil >> so jabil, when they report the quarter, it was disappointing, unquestionably was disappointing and i was able to sell the stock before it started to collapse and the stock traded down five bucks and i said, you know what? this is overstating the risk in it and it was a new position and i didn't have the full position just yet and not that it was a small size and it wasn't small i said, you know what? down here it is overdone and i bought it and i've been adding to it and they'll still talk about a $10 earnings number and t

. >>> first, to cnbc's meg tirrell on the effort to vaccinate more kids meg, this is going to look and feel a whole lot different than the first vaccine rollout, huh >> yes, shep, there are a few things that will be different this time around, aside, of course, from just smaller arms the administration today emphasizing they want to make sure the vaccine is available in places that kids and their parents know and trust, including 25,000 pediatricians and primary care offices, hundreds of childrens of hospitals, tens of thousands of pharmacies and hundreds of school and community health centers. the packaging will also change for this vaccine, to make it easier to handle in settings like doctors' offices, smaller configurations as well as smaller needles for the kids' vaccines remember e. remember, it's a third of a dose for children it will have a different color cap, a purple cap. another difference to make the rollout simpler is the vaccine can be stored in the fridge up to ten weeks it doesn't have to be kept super frozen like the original vaccine. the former can be stolen in the fr

local coverage from our nbc station in chicago in a moment first, to meg tirrell on today's booster news meg, why the half dose for moderna? >> yeah, so they looked at both, and they found that a half dose of 50 micrograms gave a big increase in the immune response with potentially fewer side effects. it's still higher than pfizer's full dose, which is 30 micrograms moderna also points out giving half doses as boosters opens up a lot more worldwide supply of the vaccine. next up for this fda committee is johnson & johnson boosters. that's on the docket for tomorrow and then we expect the fda to issue its decision on both of these vaccines within about a week now, the fda committee today was also asked to discuss when it might be appropriate to expand boosters to everybody over age 18, at least for pfizer and moderna. and the committee wasn't onboard with that idea right now with the chairman saying, quote, i don't know that the benefit has been sufficiently defined, for younger people who aren't at high risk because of their health or job setting. now, a cdc representative suggested it m

it also dramatically decreased cases of the flu, but things could be very different this year meg tirrellst year with a twin democrat, covid and flu at the same time. as you said, it did not materialize. but now we are meeting more in person we are taking off our masks. and schools are back in session. health officials are warnings it could be really different. check out how much covid dwarfed the flu last year. the numbers of deaths that were reported last week were unlike anything we ever see from flu. and flu, the white there, essentially disappeared last year which in one sense is great news but experts warning it could come back. also because we didn't have flu last year our immunity isn't there. it could be worse this year. now is the time for folks to get their flu shots. the cdc are shipping a record number to the u.s. this year, 200 million doses. about half of adults rue to anally get vaccinated, about 60% of kids. they are hoping it goes up this year the effectiveness for the flu vaccine is about 60% in the best seasons. but that's just against any flu. against hospitalizations

enough this weekend america will top yet another grim milestone 700,000 deaths from covid-19 cnbc's meg tirrell covers science and medicine for us. meg, i know you've broken down the data how promising is this? >> yeah, shep, a lot of people are very excited about this drug because it's a lot easier to take than the antibody drugs which are already out there, which of course you have to get by iv infusion or by injection so this medicine, which is called molnupiravir, is given as capsules taken twice a day for five days at the earliest signs of covid it's been compared with tamiflu, which of course is for influenza. but i talked with merck's head of research about this and he said this drug has a much bigger benefit, saying an impact like this "has not been seen in any anti-viral for a respiratory virus to date. with merck filing imminently for fod authorization, industry analysts forecast the drug could be available by the end of the year merck tested it in patients with at least one risk factor for severe disease like age or an underlying health condition, and nobody in the trial was vaccinat

cnbc's meg tirrell covers health and science for us what do the advisers have to say about mixing and matching, meg >> shep, it's clear many of them report the flexibility in boosting a cdc representative made that point, that being able to switch brands is really important from a public health perspective, like going into a nursing home to boost residents' protection with just one vaccine type, for example. what's not clear is what the fda would will do with those recommendations at this point. the data on mixing and matching boosters came from a small nih trial that looked at the antibody responses and safety of all of the different vaccine combinations we heard earlier this week the results suggest giving a pfizer or moderna folk boost to folks who originally got j&j was better than giving those folks a second j&j shot. but the fda said it has not had time to review the data and advisers did not vote on it today. so it's unclear where the agency will include that flexibility in the decision on the boosters, which is expected to issue in about a week the cdc advisers are scheduled t

at least not yet cnbc's meg tirrell covers science and health for us. why can it be so hard to find one of these things? >> experts point to a couple reasons, chiefly that the u.s. didn't prioritize having inexpensive ubiquitous tests early on the fda has approved seven tests. these are by abbott and others you can find these at stores like walmart, cvs and walgreens, except a lot of times you'll check and they'll be sold out. that's at least partly because earlier this year manufacturers cut back on making these tests or at least in one case even reportedly destroyed inventory as more people got vaccinated. the cdc said fully vaccinated people didn't need to be tested after exposure if they were showing no symptoms. that guidance changed along with the agency's mask guidance in july with the delta variant. now the u.s. is ramping up supply of these tests with the white house pledging another billion dollars to the effort and promising to quadruple the number of tests available to americans by december to 200 million per month. some advocates say that's

the lacks family, that doesn't justify what they call the exploitation of her body here's cnbc's meg tirrell. >> reporter: for ron lacks, it's a proud but complicated family legacy. >> it's like our grandmother was a superhero, you know, helping so many. >> reporter: hela cells, named for henrietta's fist and last names, offered a new tool to science. they continue to live and reproduce in the lab the cell line has been used to develop medical breakthroughs like the polio vaccine, advancements against cancer and hiv, and recently to better understand the coronavirus the cells are sold for research purposes by companies including thermo fisher scientific but the lacks family and their attorneys say the cells were stolen and the business is quote, nothing more than a perpetuation of this theft attorney ben crump says the lawsuit, which alleges unjust enrichment, names only one company now, but that his team has identified hundreds that have benefited from use of hela cells. >> these pharmaceutical companies are making billions upon billions of dollars, and henrietta lacks' family hasn't made o

with a look at how the rollout could go, here's our senior correspondent, meg tirrell >> reporter: kids are not exactly excited about getting the covid shot itself, but what it allows them to do, that's a different story. >> i would like to go to the water park i would like to go everywhere. >> going to where? >> chuck-e-cheese. >> the park. >> reporter: many parents say they want the vaccine for their kid right away so doctor's offices are getting ready. >> this is going to be all hands on deck, and it's going to be on the weekends and we're going to be, you know, running it similar to a flu clinic. >> the biden administration says there's enough supply for all 28 million kids in this age group, two doses each about 15 million are expected to be shipped right away according to the association of immunization managers, 10 million to states and jurisdictions and 5 million to pharmacies in maine, a key strategy is working with schools to help set up clinics. >> we're trying to get as many kids vaccinated as quickly as possible, principally so they can have a somewhat more normal winter ho

. >> thank you for bringing that to us, our own meg tirrell. >>> we have more after this, including developmentsure bill. don't go anywhere. with directv stream, i can get live tv and on demand together. watch: serena williams... wonder woman.... serena... wonder woman... serena... wonder woman... ♪ ♪ ace. advantage! you cannot be serious! ♪ ♪ get your tv together with the best of live and on demand. introducing directv stream. [uplifting music playing] ♪ i had a dream that someday ♪ ♪ i would just fly, fly away ♪ >>> breaking news out of washington ylan mui is back what's going on? >> kelly, house speaker nancy pelosi is announcing she wants to advance that social spending package by bringing it to the rules committee tomorrow for a hearing. now, that is a required step to -- for any package before it goes to the floor. and pelosi said that they are close to the agreement on the priorities and top line of the legislation and that they must have trust and confidence in an agreement for the build back better act however, lawmakers still do not know exactly what is in this package. but, this is an

meg tirrell, thank you for brings us that news. >>> and up next, hertz interim ceo mark fields on uber>>> and mayor barra joins us on third quarter earnings, as we head to break, check out gm and other companies to report quarterly numbers this morning gm down by about 1.3%. quk x"-davidson up by 2.5% "sawbo will be right back. in 2016, i was working at the amazon warehouse when my brother passed away. and a couple of years later, my mother passed away. after taking care of them, i knew that i really wanted to become a nurse. amazon helped me with training and tuition. today, i'm a medical assistant and i'm studying to become a registered nurse. in filipino: you'll always be in my heart. so, should all our it move to the cloud? the cloud would give us more flexibility, but we lose control. ♪ ♪ ♪ should i stay or should i go? ♪ and we need insights across our data silos, but how? ♪ if i go there will be trouble ♪ ♪ ♪ wait, we can stay and go. hpe greenlake is the platform that brings the cloud to us. ♪ should i stay or should i go now? ♪ ♪ ♪ >>> out with two big announcements, hertz and

meg tirrell joins us with the details on that. with the peer review, a disappointing news out this morning partnered with roche roche roach on this drug they were halted for a short period of time now they're down 75%. this is a company with about a three-and-a-half week mark cap before this move this morning. now, here's what happened. they were testing a covid antiviral i viral drug similar to merck's new peer review they found it missed its primary coal of reduce ining the sars vs they enrolled all comers and said two-thirds of the people were essentially young, healthy people with conditions to progressing to severe covid. they said among high risk they seen a reduction versus a placebo with the people that got the drug they are pubing their expected phase 3 results back to the second half of 20 too. they're financial to use these results to retool the plan for that trial so, you can see that merck this morning is actually rising, it's up 3.5 or 3% in the pre market they have showed to work in a phase 3 trial notably. merck en

meg tirrell joins us right now with a special guest hi, meg. >> reporter: hey, becky.is, ceo of merck thanks for being with us, rob. big quarter for merck. start with what drove the quarter. you guys seemed looking at recovery from a lot of the covid impacts. seeing it in massive keytruda number, gardasil numbers, your mmr, chicken pox vaccine doing well because of return of wellness visits. what are you seeing in terms of covid impact and what you're modeling going forward >> first of all, meg, thank you for having me on again i really appreciate the time this morning as you said, we did have an incredibly strong quarter and it's coming across all pillars of our business. you mentioned some of those within our oncology business led by keytruda, grew 22% in the quarter. vaccines led by gardasil grew 68% in the quarter and then obviously animal health business, strong growth at 16% we are seeing impact of the pandemic largely receding, and really have strong underlying demand and good momentum in the business right now that i feel really good about. >> so you didn't inc

meg tirrell has that story hi, meg. >> hey we were warned about this last year and that twindemic did this year because we are backing often on masking and social distancing and schools back in session we are warped that this could be a severe flu season and not just because of those reasons but didn't have flu last year health officials warn we have less population immunity and it could be more severe coming back they also warn that we have seen a return of other respiratory viruses like rsv all of these things are bad warning signs and worried what could be to come here's the cdc director warning about this yesterday >> we are worried that having not seen the respiratory viruses last year taking the prevention mitt gags strategies we may see more of them in the year ahead >> so health officials say now's the time 0 get the flu shot if you haven't already. they expect manufacturers to ship a record number to the u.s. this year up to 200 million doses. and guys we often hear the flu shot is not as effective as the covid season 60% but that's against any kind of flu and good to keep fo

meg tirrell with the news. mega >> hi, sara.et's start with the pfizer news today as a study published which essentially we knew about from the booster discussion showing that after six months you see a decline in pfizer and buy i don't know tech vaccine's effectiveness against infection from 88% one month after full vaccination to 47% up to 6 months later good news from the study 93% protection against hospitalizations associated with the delta variant. still strong protection there and this played boo the booster discussions and this morning news that johnson & johnson filed an application with the fda for a booster. this ahead of the fda meetings october 14 and 15. that's end of next week for moderna's and j&j's booster and a presentation of data on mixing and matching the boosters so that's fascinating to watch and then ahead of the fda advisory committee talking about pfizer's application for kids 5 to 11 a busy month at the fda. over on the dru reviewing side looking at an astrazeneca application for covid antibody cocktai

. >>> there's growing concern of the delta plus covid variant meg tirrell with the details tweeting aboutorried. >> i do, too hearing about a new variant is really horrible news but the jury is out about how dangerous this potential new variant yes yesterday warning on twitter about the rides of this variant that's a sub strain of delta variant and right now he said 8% of cases in the uk and the steady rise coincided with an uptick in cases in the uk and cases have been rising there and essentially he notes that this is prevalent there or at least present there since july and steadily slowly gaining in pre lens and i have been talking about whether this is concerning they say it's not clear. one analysis suggest based on the data it could be potentially 10% more transmissible than delta. virologists say it's not clear that it would be gottlieb concluding yesterday that this is not a cause for concern right now and seem to be similar as international efforts standard practice in flu so one to keep an eye on and one that people pay attention to and could be a variant of interest but right n

meg tirrell with the latest on the vaccines mike, respectable follow through today. >> absolutely. more than one half of a percent upside after yesterday's big surge. has climbed, the s&p 500, above the 50-day average stopping yesterday. the next thing to look for is one month ago september 15th in the 4480 range this market hustles and symmetrical with the low early last week and have stair stepped up from there and can't guarantee an all clear but a lot of the things to want to see lining up to say that you got a pretty plausible seasonable low and they are getting into place and the market never really did let go of the cyclical bias. look at the chart of things geared to rae covering economy and slowdown trades. this is consumer discretionary all equal weighted no two stocks in a sector dominate as you can see, good separation all year now mostly sideways for the cyclicals and nosing above that consumer discretionary it of can get to a new high and the s&p financials today getting to a new all-time high and seen a rekindling of the excitement in some of the most speculative par

we'll talk with the ceo of ftx >>> first mike santoli is tracking the market action meg tirrell to talk about merck and, mike, let's start with you. healthy looking intraday chart. >> some pressure coming off after the weak close yesterday i think that the merck news this morning taken as a positive. as well as we got this extra leg higher once we saw the reports that president biden heading to capitol hill maybe so that people didn't get too negative that's just kind of conjecture and the first day of a new quarter is positive in recent quarters so we are seeing the effects. this is where we were midday yesterday and did just tack yesterday afternoon's or morning. the highs of the every day this week around 36, 4380 a little bit above here. trying to kind of gather itself here the next step down are the mid-july lows. like 4250. that's the tactical technical picture. market in general has a reset here been talking for a while about under the surface weakness here's the russell 1000. going sideways did nothing going back to april and sort of below where we hit in early june whereas the

we're getting breaking news from the fda advisory committee, they're meeting on vaccines for kids meg tirrell, 0 no, with one abstention. so overwhelmingly recommending that the fda clear this vaccine through emergency use authorization for that age group. but that overwhelmingly positive vote really sort of doesn't reveal the amount of debate that happened from this committee today. a lot of the advisers were asking if the recommendation could perhaps be narrowed to more at-risk kids. there was a lot of debate over the benefit risk because of the unknown risk of myocarditis, the rare heart related side effect that has been seen predominantly among young men after the second dose of mrna vaccines. this is a third of the dose of the adult vaccine, so there was a lot of debate whether there will be much of this seen in the younger kids population. the fda doing a lot of modeling and ultimately, the fda came down on the side that the benefit did outweigh the risk. now this goes to the fda to make its decision after that, it will go to a cdc committee next week to make recommendations on how the

meg tirrell with the story >> hi, sarah the fda authorizing a new at home rapid antigen test for covidd at home testing capacity in the u.s. over the next several weeks they say by the end of the year this company plans to produce more than 100 million tests per month, getting up to 200 million per month by february 2022 it's been hard to find those binax now tests. >> bring it on >> thank you very much it will be interesting to see a bounce >> getting a little bit stretched. we're trading pretty technically here, 4,300, 1%, 1.5%. people are watching the s&p. >>> that does it for "closing bell." "fast money" starts now. >>> live from the nasdaq market site overlook new york city's time square, this is "fast money. i'm melissa lee. guy adami, tim seymour, karen finerman, and pete najarian. tonight, facebook shares plunging 5% as a whistle-blower sounds the alarm and the company is hit with a massive service disruption we're breaking down the fallout straight ahead >>> plus tesla holding in the green despite today's selloff. we'll bring you the big number that had investors driving into

meg tirrell with the latest details on novavax and abbott labs we've got covid vaccines and testing.avax heading lower today after a "politico" report last night citing anonymous sources suggesting the company is having major manufacturing issues that puts in jeopardy the availability of that vaccine both here and around the world, which is really disappointing from a global vaccine access standpoint because this was a vaccine that was really supposed to help with the global effort so the stock down nearly 16% the company saying that it has confidence in its manufacturing and its ability to deliver this vaccine, saying that it plans to file for emergency use authorization in the u.s. by the end of the year. but, of course, this weighing on the stock. and we've seen multiple delays from this company already. abbott labs beating expectations with its third quarter results today, and positing just a blow-away number, $1.9 billion in covid testing revenue for the quarter, forecasting up to 1.4 b 1.4 billion in the fourth quarter. a lot of this driven by the rapid testing sales. binax now

a phase 3 trial shows high efficacy for the booster and the variants meg tirrell is joining us now. i am assuming, tell me i'm right. if i am wrong, i have to go back and correct myself that this will be the booster for everybody, not just the elderly or those immunocompromised? >> well, this is the booster that could be for everybody. currently, the pfizer folks are only authorized in those specific groups. let's actually go over that. because last night, we got the word from the fda that boosters for everybody or at least the groups for each vaccine have been authorized. so now moderna and j&j folks are on track to get boosters, too. this is how it breaks down, essentially for j&j, everybody two months out can go get another booster. it is basically any beers they want, they can mix or match, get a pfizer or a half dose of moderna, moderna boosters were authorized for folks out in those high risk groups, either people over 65 or at high risk because of their health or exposure rick. again, pfizer folks can get j&j. same goes for pfizer this morning, what we got was efficacy data fr

it's pretty phenomenal meg tirrell is back. she has the details. hey, meg >> hey, becky.phase 3 results we were waiting for, the first covid-19 pill in a large study it reduced the risk of hospitalization or death by 48% when given twice daily for five days to people with one risk factor for severe covid now the results were so positive merck says its independent data advisory committee recommended stopping early in consultation with the fda they decided to do that and will seek emergency use as soon as possible they measured that 50% reduction is they have about 775 patients enrolled as of this interim look they found that 14% of plashts on placebo were hospitalized or died one month after their diagnosis with covid that compares to 7.3% with people that got the drug so there is a real reduction in risk there now in terms of supply, the u.s. ordered 1.7 million courses for 1.2 billion. merck says it can make 10 million by the end of the year so we'll have to see how this gets through the fda in this trial, it was only unvaccinated folks will that be the indication where